Aldeyra Hits Primary Endpoint in Part 1 of Phase 3 Vitreoretinopathy Trial

 

• ADX-2191 Statistically Superior to Historical Control for Primary Endpoint of Prevention of Retinal Detachment (P=0.024)

• Numerical Superiority of ADX-2191 over Routine Surgical Care Achieved for Majority of Secondary, Exploratory, and Safety Endpoints

• ADX-2191 Observed to be Well Tolerated with No Safety Concerns Noted

• Company Plans to Discuss Completion of Clinical Development in Proliferative Vitreoretinopathy with the U.S. Food and Drug Administration in the First Half of 2023

• Company to Host Conference Call at 8:00 a.m. ET Today

Aldeyra will host a conference call to discuss this announcement at 8:00 a.m. ET today, October 6, 2022. The dial-in numbers are (844) 200-6205 for domestic callers and (646) 904-5544 for international callers. The access code is 005042. A live webcast of the conference call will also be available on the "Investors & Media" section of the Aldeyra website at https://ir.aldeyra.com. Presentation slides, which contain material information and should be reviewed in conjunction with this press release, will be available on the investor relations page prior to the start of the conference call and webcast.

After the live webcast, the event will remain archived on the Aldeyra website for 90 days.

https://finance.yahoo.com/news/aldeyra-therapeutics-achieves-primary-endpoint-110000149.html